Chunhui Han, PhD, discusses the potential feasibility of the integration of Gallium 68 PSMA-11 in biology-guided radiotherapy ...

Joe DePinto, MBA, discusses some of the key challenges to equitable access to cell and gene therapies, especially in ...

Shubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2-positive biliary tract cancer ...

A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety ...

Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.

In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive ...

Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node ...

Invikafusp alfa showed promise as a treatment option across a range of high tumor mutational burden cancers or virally ...

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple ...

During a Case-Based Roundtable® event, Omar Nadeem, MD, and participants reacted to data from the MonumenTAL-1 trial in the ...

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate ...

Along with the Oncology Brothers, Paolo Tarantino, MD, provides an overview of the pPhase 3 EMERALD study, which evaluates the efficacy of elacestrant as a second-line treatment for ER+/HER2–- ...